<DOCUMENT>
<TYPE>TEXT-EXTRACT
<SEQUENCE>2
<FILENAME>filename2.txt
<TEXT>
                                                            April 11, 2019

Sunil Bhonsle
Chief Executive Officer
Titan Pharmaceuticals, Inc.
400 Oyster Point Boulevard
South San Francisco, CA 94080

       Re: Titan Pharmaceuticals, Inc.
           Registration Statement on Form S-3
           Filed April 5, 2019
           File No. 333-230742

Dear Mr. Bhonsle:

       We have limited our review of your registration statement to those
issues we have
addressed in our comments. In some of our comments, we may ask you to provide
us with
information so we may better understand your disclosure.

       Please respond to this letter by amending your registration statement
and providing the
requested information. If you do not believe our comments apply to your facts
and
circumstances or do not believe an amendment is appropriate, please tell us why
in your
response.

       After reviewing any amendment to your registration statement and the
information you
provide in response to these comments, we may have additional comments.

Registration Statement on Form S-3

Exhibits

1.     Please file the form of indentures, Exhibits 4.2 and 4.3, with the next
amendment. Please
       note that the form of indentures must be filed before we act on a
request for acceleration
       regarding your Form S-3.
        We remind you that the company and its management are responsible for
the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action
or absence of
action by the staff.

       Refer to Rules 460 and 461 regarding requests for acceleration. Please
allow adequate
time for us to review any amendment prior to the requested effective date of
the registration
statement.
 Sunil Bhonsle
Titan Pharmaceuticals, Inc.
April 11, 2019
Page 2

       Please contact Donald Field at 202-551-3680 or Dietrich King at
202-551-8071 with
any questions.



FirstName LastNameSunil Bhonsle                          Sincerely,
Comapany NameTitan Pharmaceuticals, Inc.
                                                         Division of
Corporation Finance
April 11, 2019 Page 2                                    Office of Healthcare &
Insurance
FirstName LastName
</TEXT>
</DOCUMENT>
